Allergan plc AGN along with Hungary’s Gedeon Richter Plc announced that the FDA has approved a supplemental new drug application (sNDA) of its schizophrenia drug, Vraylar (cariprazine). The company ...

Allergan plcAGN and Hungary-based partner Gedeon Richter Plc. have announced positive top-line results from the third pivotal study, evaluating the companies' schizophrenia drug Vraylar (cariprazine) ...

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Vraylar" report has been added to ResearchAndMarkets.com's offering. Vraylar (cariprazine; Gedeon Richter/Allergan ...

Please provide your email address to receive an email when new articles are posted on . Allergan recently announced that Vraylar, a once-daily oral atypical antipsychotic, is now available by ...

Allergan plcAGN, along with partner Gedeon Richter, announced positive top-line results from a second pivotal phase III study on its schizophrenia drug Vraylar. The study evaluated Vraylar ...

Allergan, badly in need of good news, finally has some to share with investors. On Tuesday, the FDA greenlighted the company’s antipsychotic med Vraylar to treat depression in adults with bipolar ...

Vraylar (cariprazine) is a powerful antipsychotic medication that is approved by the Food and Drug Administration (FDA) to treat schizophrenia, bipolar disorder, and major depressive disorder (MDD).

Please provide your email address to receive an email when new articles are posted on . The FDA today approved Vraylar to treat schizophrenia and bipolar disorder in adults, according to a press ...